Held by 7 specialist biotech funds
High Convergence# Signal Note: RTW Investments Initiates $270M Position in COGT RTW's substantial entry suggests conviction in Cogent's pipeline, likely driven by upcoming catalysts around seribantumab (a MET inhibitor) in non-small cell lung cancer and gastric cancer indications, where clinical data readouts could unlock valuation.
AI analyst context — unlock full analysis
**Signal Note: Commodore Capital initiates $78M position in COGT** Pellini's entry suggests confidence in Cogent's pipeline, likely centered on seribantumab (AMG 510 collaboration partner role) for KRAS-mutant cancers or pluvicto expansion opportunities post-Novartis acquisition. The $78M stake (meaningful for a ~$250M market cap company) from a precision oncology-focused investor with Foundation Medicine pedigree indicates conviction in near-term catalysts, potentially including clinical data readouts or partnership announcements in 2024-2025.
+ 5more — see how much conviction went in
See the Full Story